Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00413283 · ClinicalTrials.gov registry record · Phase 2

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 study of Cancer and Non-Small Cell Lung Cancer, sponsored by Amgen.

Completed
Registry status
Phase 2
Development phase
63
Enrollment target
20
Study locations

NCT00413283 is a Phase 2 study of Cancer and Non-Small Cell Lung Cancer that has completed, run by Amgen. The registered enrollment target is 63 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00413283, a Phase 2 study of Cancer and Non-Small Cell Lung Cancer, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 2
Development phase
63 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

Conditions Studied

Cancer Non-Small Cell Lung Cancer Lung Cancer Solid Tumors Oncology Lung Neoplasms Thrombocytopenia Chemotherapy Induced Thrombocytopenia

Interventions

  • DRUG Carboplatin
  • DRUG Placebo
  • DRUG Cisplatin
  • DRUG Gemcitabine
  • BIOLOGICAL Romiplostim

Study Locations (20)

California

  • Research Site - Anaheim
  • Research Site - Anaheim
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Rancho Mirage
  • Research Site - Rancho Mirage

Florida

  • Research Site - Boynton Beach
  • Research Site - Boynton Beach
  • Research Site - Vero Beach
  • Research Site - Vero Beach

Georgia

  • Research Site - Athens
  • Research Site - Athens
  • Research Site - Macon
  • Research Site - Macon

Arizona

  • Research Site - Glendale
  • Research Site - Glendale

Illinois

  • Research Site - Peoria
  • Research Site - Peoria

Iowa

  • Research Site - Sioux City
  • Research Site - Sioux City

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2006-12
Est. Completion 2009-02
Phase Phase 2

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00413283

The ClinicalTrials.gov registry entry for NCT00413283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT00413283 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00413283 about?

NCT00413283 is a clinical study titled "Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

What is the current status of trial NCT00413283?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-12. Estimated completion is 2009-02.

What conditions does trial NCT00413283 study?

This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Solid Tumors, Oncology.

What interventions are being tested in trial NCT00413283?

The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Romiplostim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00413283?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00413283 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.